Turnover of GlaxoSmithKline was US$44 billion in 2013 and it annually spends $6.5 billion in R&D. Its sales data is public information while results of R&D had been the best kept secret until October 2012. Two years ago the British pharmaceutical behemoth has stunned the scientific community when it decided to share the detailed data of its clinical trials. No, it was not a cheap marketing stunt, as MIT Technology Review reports: In May 2013, the company began posting its own data online.